Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Thalidomide and Tegafur/Uracil(UFUR) in the Treatment of Advanced Colorectal Cancer

. Thalidomide is an agent, which has shown potential in the treatment of hematological and solid tissue malignancies such as multiple myeloma via antiangiogenic mechanism. Tegafur/uracil (UFUR) is one

metastasis
neutrophil count
antineoplastic
oxaliplatin
measurable disease
  • 7 views
  • 07 Nov, 2020
  • 1 location
A Phase II Study of Tegafur/Uracil (UFUR )Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Primary objective: To evaluate the overall response rate of tegafur/uracil (UFUR®) and thalidomide in the treatment of advanced or metastatic hepatocellular carcinoma. Secondary

thalidomide
hepatitis
measurable disease
local therapy
metastatic hepatocellular carcinoma
  • 4 views
  • 07 Nov, 2020
  • 1 location
Uracil and Tegafur/Leucovorin (UFT/LV) Versus UFT/LV+ Polysaccharide-K (PSK) for Stage IIIa/IIIb Colorectal Cancer

The purpose of this study is to conduct a randomised controlled trial (RCT) comparing UFT/LV and UFT/LV + PSK in patients with histological stage IIIa/IIIb colorectal cancer who have undergone curative surgery without residual cancer using 3-year disease free survival (DFS) as the primary endpoint, and also to analyze the …

platelet count
leucovorin
calcium
adenocarcinoma
rectal carcinoma
  • 4 views
  • 07 Nov, 2020
  • 1 location
Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)

The purpose of this prospective randomized controlled study is to prove the non-inferiority of UFT maintenance therapy to BCG maintenance therapy for preventing recurrences of superficial bladder cancer.

cancer
transurethral resection
bladder tumor
superficial bladder cancer
intravesical administration
  • 20 views
  • 08 Nov, 2020
  • 1 location
Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)

This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the safety of tegafur gimeracil oteracil potassium capsule plus

  • 0 views
  • 26 Jan, 2021
  • 6 locations
Study of Adjuvant ONO-4538 With Resected Gastric Cancer

The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or

carcinoma
adenocarcinoma
capecitabine
gastric adenocarcinoma
gastrectomy
  • 174 views
  • 25 Jan, 2021
  • 107 locations
SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

Fluorouracil combined with oxaliplatin are routinely recommended to patients with pathological stage III (p-stage III) colorectal cancer, leading to significant improvement of 5-year disease-free survival and overall survival (approximately 3.4% -4.2%) by by international guidelines such as the National Cancer Comprehensive Network. The Considerable proportion of patients suffer with hand-foot …

  • 0 views
  • 23 Jan, 2021
  • 1 location
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior …

cancer
pembrolizumab
HER2
fluorouracil
capecitabine
  • 303 views
  • 18 Jan, 2021
  • 199 locations
Pharmacokinetic and Pharmacodynamic Study of S-1 in Patients With Digestive Organ Cancer

S-1 is a novel oral fluorouracil antitumor drug that consists of tegafur which is a prodrug of 5-fluorouracil (5-FU); 5-chloro-2,4-dihydropyridine (CDHP), which inhibits dihydropyrimidine

cancer
tegafur
fluorouracil
potassium
gimeracil
  • 7 views
  • 07 Nov, 2020
  • 1 location
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

regimen in patients with advanced NSCLC pretreated with non-platinum based chemotherapy. TS-1 (Jeil Pharmaceutical Co.,Ltd, Seoul, Korea) is an oral anticancer drug comprised of tegafur

  • 10 views
  • 07 Nov, 2020
  • 1 location